IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by FARMERS & MERCHANTS TRUST Co OF LONG BEACH

FARMERS & MERCHANTS TRUST Co OF LONG BEACH decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,420 shares of the company’s stock after selling 90 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in IDEXX Laboratories were worth $767,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in IDXX. Allspring Global Investments Holdings LLC grew its holdings in IDEXX Laboratories by 10.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 40,771 shares of the company’s stock valued at $22,013,000 after purchasing an additional 3,886 shares in the last quarter. Oak Thistle LLC acquired a new stake in IDEXX Laboratories during the 1st quarter valued at $297,000. Aviance Capital Partners LLC bought a new position in IDEXX Laboratories during the 1st quarter valued at $405,000. Vicus Capital bought a new position in IDEXX Laboratories during the 1st quarter valued at $210,000. Finally, OneAscent Wealth Management LLC bought a new position in IDEXX Laboratories during the 1st quarter valued at $206,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, June 14th. Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research report on Monday, June 24th. Barclays reduced their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Finally, William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $586.63.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the sale, the director now directly owns 161 shares of the company’s stock, valued at approximately $87,068.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.18% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded up $0.73 during trading hours on Tuesday, reaching $477.13. The stock had a trading volume of 96,473 shares, compared to its average volume of 471,883. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The firm has a 50-day simple moving average of $501.58 and a 200-day simple moving average of $526.59. The firm has a market capitalization of $39.41 billion, a PE ratio of 46.12, a price-to-earnings-growth ratio of 3.97 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The business had revenue of $964.10 million for the quarter, compared to analysts’ expectations of $965.43 million. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.